Nasal Spray Shows Promise in Reversing Brain Aging in Early Studies
A new nasal spray developed by researchers at Texas A&M University is showing early promise in reversing signs of brain aging in animal models, according to recent findings. The treatment, which uses extracellular vesicles derived from stem cells, appears to reduce neuroinflammation and improve memory in aged mice when administered through the nose. This non-invasive approach could one day offer a simple way to combat age-related cognitive decline, though experts caution that human applications remain years away.
The research centers on tiny biological particles called extracellular vesicles (EVs), which are naturally released by cells and carry molecular signals like microRNA between tissues. In this case, scientists isolated EVs from stem cells and loaded them with specific microRNA molecules known to regulate gene activity in the brain. When delivered as a nasal spray, these vesicles were able to bypass part of the blood-brain barrier—a protective shield that often blocks drugs from reaching the brain—and accumulate in regions critical for memory, such as the hippocampus.
In experiments with aging mice, two doses of the nasal spray led to measurable improvements in memory and learning tasks. Researchers observed reduced inflammation in the brain and enhanced neural function, suggesting the treatment may help reverse some effects of cognitive aging. The study, led by Dr. Ashok Shetty and colleagues Madhu Leelavathi Narayana and Maheedhar Kodali, was reported in early 2026 and has since been highlighted by multiple science outlets as a potential breakthrough in neurology.
While the results are promising, the research remains in the preclinical stage, meaning it has only been tested in laboratory animals. No human trials have been conducted yet and scientists emphasize that much more study is needed to determine safety, optimal dosage, and long-term effects in people. The nasal delivery method is particularly notable since it avoids invasive procedures like injections or surgery, making it a potentially accessible option if proven effective in humans.
Experts in neurodegenerative diseases say that targeting neuroinflammation—a key driver of brain aging and conditions like Alzheimer’s—represents a sensible strategy. Chronic inflammation in the brain contributes to the gradual loss of neurons and synapses, impairing communication between brain cells. By delivering anti-inflammatory signals directly to affected areas, the nasal spray may help restore balance in the brain’s immune environment.
Still, researchers urge caution against overinterpreting early animal results. Many treatments that show promise in mice fail to translate to humans due to differences in biology, metabolism, and disease progression. The team at Texas A&M plans to continue studying the mechanism of action and eventually move toward clinical trials, but no timeline for human testing has been established.
As of April 2026, the study has not been published in a major peer-reviewed journal, and independent verification of the data is limited. The findings were first shared through university press releases and science news platforms, but experts recommend waiting for formal publication and replication by other labs before drawing firm conclusions.
For now, the nasal spray remains an experimental tool with potential, not a proven treatment. Individuals concerned about memory loss or cognitive decline should consult healthcare providers and rely on established approaches such as regular exercise, a balanced diet, mental stimulation, and managing cardiovascular risk factors—all of which have stronger evidence supporting brain health in aging.
If you found this informative, consider sharing it with others who might be interested in emerging neuroscience research. Comments are welcome below.